论文部分内容阅读
血糖控制不佳的2型糖尿病患者305例经短期CSII治疗后换为不同治疗方案,分A组:口服降糖药或联合基础胰岛素治疗组,B组:预混胰岛素类似物治疗组,比较各组临床特征并作相关分析结果与A组比较B组体重指数较低,CSII治疗末日胰岛素用量较大,差异有统计学意义(P均<0.01)。患者是否需要预混胰岛素治疗与体重指数呈负相关(r=0.429,P=0.00),与CSII治疗末日剂量呈正相关(r=0.375,P=0.003)。结论经短程CSII治疗后可以根据体重指数、CSII末日剂量粗略判断患者是否需要预混胰岛素类似物治疗。
305 patients with type 2 diabetes with poor glycemic control were treated with short-term CSII treatment and then switched to different treatment groups, divided into group A: oral hypoglycemic agents or combined with basal insulin treatment group, group B: premixed insulin analogue treatment groups, Compared with group A, the body mass index of group B was lower than that of group A, and the dosage of insulin at the end of CSII treatment was larger, the difference was statistically significant (all P <0.01). There was a negative correlation between the patients’ need for premixed insulin therapy and body mass index (r = 0.429, P = 0.00), which was positively correlated with the final dose of CSII (r = 0.375, P = 0.003). Conclusion After short-course CSII treatment, we can roughly determine whether the patients need premixed insulin analogue therapy based on body mass index and end-dose of CSII.